ACOSOG Competing Renewal

ACOSOG 竞争更新

• 批准号: 8322924
• 负责人: DAVID M. OTA
• 金额: $ 119.81万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-05-15 至 2011-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8322924
• 关键词: Address; Advocate; American College of Surgeons Oncology Group; Area; Basic Science; Breast; Cancer Patient; Caring; Chest; Clinical Research; Clinical Trials; Community Practice; Conduct Clinical Trials; Correlative Study; Data; Data Analyses; Diagnostic; Discipline; Disease; Esophagus; Goals; Health Professional; Image; Individual; Information Technology; Investigation; Lead; Lung; Mayo Clinic Cancer Center; Medical Oncologist; Mission; Modality; Molecular Profiling; Monitor; Morbidity - disease rate; Neoadjuvant Therapy; Nurses; Operative Surgical Procedures; Outcome; Pancreas; Pathologist; Patients; Peer Review; Play; Process; Quality of life; Radiation Oncologist; Rectum; Research Design; Research Infrastructure; Research Institute; Research Personnel; Review Committee; Risk; Science; Scientist; Specimen; Stratification; Support System; Surgical Management; Surgical Oncologist; Surgical Oncology; Testing; Toxic effect; Training and Education; Translational Research; Universities; Washington; base; cancer care; cancer therapy; data management; disability; gastrointestinal; improved; innovation; interdisciplinary approach; interest; member; novel; operation; programs; response; statistics

DESCRIPTION (Provided by applicant): ACOSOG is a cooperative group comprised of practicing medical, radiation, and surgical oncologists, diagnostic imagers, patient advocates, pathologists, basic scientists, nurses/CRAs, statisticians, and other healthcare professionals representing academic and community practices throughout the U.S. The purpose of ACOSOG is to develop and evaluate innovative cancer therapies in which the surgical management of cancer patients plays a key role. ACOSOG Is dedicated to Improving the care of the surgical oncology patient through an Innovative clinical research program addressing three specific aims: 1. To test novel therapies that may increase response and cure rates and reduce morbidities and disabilities associated with cancer care 2. To conduct basic science studies in conjunction with clinical trials to better understand the biologic basis of diseases and treatments. 3. To support Individual members and investigator networks to accrue patients to trials and fulfill the scientific mission of ACOSOG. The scientific portfolio of ACOSOG is focused on investigations addressing three scientific aims for ACOSOG trials: 1) to investigate novel surgical and targeted therapies to maintain oncologic outcomes while reducing toxicities and disabilities and Improving quality of life; 2) to enhance the accuracy of risk stratification through imaging and molecular profiling; and 3) to Improve overall response rates and monitor Individual responses through the application of neoadjuvant therapies. The scientific agenda is established by the Basic and Translational Science Committee and the three Disease Committees: Breast, Gastrointestinal (GIST, pancreas, and rectum), and Thoracic (lung and esophagus) and maintained and prioritized by the ACOSOG Peer Review Committees. A multidisciplinary approach to the scientific agenda is accomplished through the comprehensive integration of all modalities and disciplines. Membership interests, needs, and oversight are attended to through the actions of seven Administrative Committees. To accomplish the goals of ACOSOG, the group conducts clinical trials and correlative studies using an infrastructure consisting of three critical components Including: 1) the Operations and Membership Center (OMC) located in Durham, NC, within the Duke Clinical Research Institute; 2) the Statistics and Data Center (SDC) located In Rochester, MN, within the Mayo Clinic Cancer Center; and 3) the Central Specimen Bank (U24 # 5 U24 CA114736) located in St. Louis, MO, within the Washington University.

描述（申请人提供）：ACOSOG是一个合作小组，由执业医学、放射和外科肿瘤学家、诊断成像师、患者倡导者、病理学家、基础科学家、护士/CRA、统计学家组成，ACOSOG的目的是开发和评估创新的癌症治疗方法，其中癌症的手术管理病人起着关键作用。ACOSOG致力于通过创新的临床研究计划来改善外科肿瘤患者的护理，该计划涉及三个具体目标：1。测试可能增加反应和治愈率并减少与癌症护理相关的发病率和残疾的新疗法 2.进行基础科学研究与临床试验，以更好地了解疾病和治疗的生物学基础。 3.支持个人成员和研究者网络招募患者参加试验，并履行ACOSOG的科学使命。 ACOSOG的科学组合专注于解决ACOSOG试验的三个科学目标的研究：1）研究新的手术和靶向治疗，以维持肿瘤学结局，同时减少毒性和残疾并改善生活质量; 2）通过成像和分子分析提高风险分层的准确性;和3）通过应用新辅助疗法提高总体反应率并监测个体反应。科学议程由基础和转化科学委员会和三个疾病委员会制定：乳腺、胃肠道（GIST、胰腺和直肠）和胸部（肺和食管），并由ACOSOG同行评审委员会维护和优先考虑。通过全面整合所有模式和学科，实现了对科学议程的多学科方法。会员的利益、需求和监督通过七个行政委员会的行动得到满足。为了实现ACOSOG的目标，该小组使用由三个关键组成部分组成的基础设施进行临床试验和相关研究，包括：1）位于杜克临床研究所内达勒姆的运营和会员中心（OMC）; 2）位于马约诊所癌症中心内罗切斯特的统计和数据中心（SDC）;以及3）位于密苏里州圣路易斯市的中央标本库（U24 # 5 U24 CA 114736），位于华盛顿大学内。